Company / Current Liabilities
Inhibrx Biosciences, Inc. Current Liabilities History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$33.8M
FY2025
5-year range
$33.8M / $56.3M
FY2023-FY2025
Trend
-17.0%
vs FY2024
Sector context
#171 of 213
Health Care
What the data says
Inhibrx Biosciences, Inc.'s current liabilities of $34M is lower than 80% of companies in the Health Care sector (FY2025). Improved from $56M to $34M over the past 2 years.
Based on SEC 10-K filings.
$34M in FY2025.
Improved from $56M to $34M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 213This company $33.8M Sector average $1.6B
▼
-97.9% below sector average
Key checks
Key Insights
- In FY2025, current liabilities decreased 17.0% year-over-year.
- Ranks #171 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $33.8M | -17.0% |
| FY2024 | $40.7M | -27.7% |
| FY2023 | $56.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026